Cardiovascular risk in chronic renal disease and transplantation prevention and management

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 6, 2005, Pages 929-943

  Malyszko, Jolanta ^a   Malyszko, Jacek S ^a   Bachorzewska Gajewska, Hanna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acute coronary syndromes; Chronic renal failure; Coronary artery bypass grafting; Coronary artery disease; Dialysis; Kidney transplant recipients; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPTIFIBATIDE; ERYTHROPOIETIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FLUINDOSTATIN; GEMFIBROZIL; GLIPIZIDE; HEPARIN; INSULIN; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; NICOTINIC ACID; NITRATE; PLACEBO; PRAVASTATIN; RAPAMYCIN; ROSIGLITAZONE; SIMVASTATIN; STEROID; TACROLIMUS; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART INFARCTION; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; KIDNEY ALLOGRAFT REJECTION; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MORTALITY; MYOPATHY; OUTCOMES RESEARCH; PREVENTION; RECIPIENT; REVIEW; SIDE EFFECT; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 21844433473     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.6.929     Document Type: Review

References (121)

1. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC et al.: Kidney disease as a risk factor for development of cardiovacular disease: a statement from the American heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure, Clinical Cardiology, and Epidemiology and Prevention. Circulation (2003) 108:2154-2169.
2. US Renal Data System: USDRS 2002 Annual Data Report. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. (2003).
3. SARNAK MJ, LEVEY AS: Epidemiology of cardiac disease in dialysis patients. Semin. Dial. (1999) 12:69-75.
4. LONGENECKER JC, CORESH J, POWE NR et al.: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J. Am. Soc. Nephrol. (2002) 13(7):1918-1927.
5. KARNIK JA, YOUNG BS, LEW NL et al.: Cardiac arrest and sudden death in dialysis units. Kidney Int. (2001) 60(1):350-357.
6. BLEYER AJ, RUSSELL GB, SATKO SG: Sudden and cardiac death rates in hemodialysis patients. Kidney Int. (1999) 55(4):1553-1559.
7. KOCHERIL AG: Arrhythmia issues in patients with renal disease. Semin. Nephrol. (2001) 21:57-65.
8. STEWART GA, GANSEVOORT RT, MARK PB et al.: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. (2005) 67(1):217-226.
9. MCCULLOUGH PA, SANDBERG KR: Chronic kidney disease and sudden death: strategies for prevention. Blood Purif. (2004) 22(1):136-142.
10. WRIGHT RS, REEDER GS, HERZOG CA et al.: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann. Intern. Med. (2002) 137(7):563-570.
11. KASISKE BL, GUIJARRO C, MASSY ZA, WIEDERKEHR MR, MA JZ: Cardiovascular disease after renal transplantation. J. Am. Soc. Nephrol. (1996) 7:158-165.
12. KASISKE BL, CHAKKERA HA, ROEL J: Explained and unexplained ischemic heart disease in renal transplant recipients. J. Am. Soc. Nephrol. (2000) 11:1735-1740.
13. KEW CE, CURTIS JJ: Cardiovascular disease in kidney transplant recipients. Curr. Opin. Organ Transplant. (1998) 3:183-187.
14. MEIER-KRIESCHE HU, KAPLAN B: Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation (2002) 74(10):1377-1381.
15. CULLETON BF, LARSON MG, WILSON PW, EVANS JC, PARFREY PS, LEVY D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. (1999) 56(6):2214-2219.
16. GARG AX, CLARK WF, HAYNES RB, HOUSE AA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. (2002) 61(4):1486-1494.
17. MUNTNER P, HE J, HAMM L, LORIA C, WHELTON PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J. Am. Soc. Nephrol. (2002) 13(3):745-753.
18. MANJUNATH G, TIGHIOUART H, IBRAHIM H et al.: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J. Am. Coll. Cardiol. (2003) 41(1):47-55.
19. HILLEGE HL, FIDLER V, DIERCKS GF et al.: Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 106(14):1777-1782.
20. WEINER DE, TIGHIOUART H, AMIN MG et al.: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. (2004) 15(5):1307-1315.
21. SHULMAN NB, FORD CE, HALL WD et al.: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension (1989) 13(5 Suppl.):I80-I93.
22. FOLEY RN, MURRAY AM, LI S et al.: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J. Am. Soc. Nephrol. (2005) 16(2):489-495.
23. RUILOPE LM, SALVETTI A, JAMERSON K et al.: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. (2001) 12(2):218-225.
24. MANN JF, GERSTEIN HC, POGUE J, BOSCH J, YUSUF S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. (2001) 134(8):629-636.
25. HEMMELGARN BR, GHALI WA, QUAN H et al.: Poor long-term survival after coronary angiography in patients with renal insufficiency. Am. J. Kidney Dis. (2001) 37(1):64-72.
26. SEGURA J, CAMPO C, GIL P et al.: Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J. Am. Soc. Nephrol. (2004) 15(6):1616-1622.
27. KEITH DS, NICHOLS GA, GULLION CM, BROWN JB, SMITH DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. (2004) 164(6):659-663.
28. IX JH, SHLIPAK MG, LIU HH, SCHILLER NB, WHOOLEY MA: Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J. Am. Soc. Nephrol. (2003) 14(12):3233-3238.
29. HILL MN, GROSSMAN RA, FELDMAN HI, HURWITZ S, DAFOE DC: Changes in causes of death after renal transplantation, 1966 to 1987. Am. J. Kidney Dis. (1991) 17(5):512-518.
30. YEO FE, VILLINES TC, BUCCI JR, TAYLOR AJ, ABBOTT KC: Cardiovascular risk in stage 4 and 5 nephropathy. Adv. Chronic Kidney Dis. (2004) 11(2):116-133.
31. FOLEY RN, HERZOG CA, COLLINS AJ: Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int. (2003) 63(4):1462-1467.
32. KASISKE BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am. J. Med. (1988) 84(6):985-992.
33. RIGATTO C, PARFREY P, FOLEY R, NEGRIJN C, TRIBULA C, JEFFERY J: Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J. Am. Soc. Nephrol. (2002) 13(4):1084-1090.
34. DUCLOUX D, MOTTE G, CHALLIER B, GIBEY R, CHALOPIN JM: Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J. Am. Soc. Nephrol. (2000) 11(1):134-137.
35. MEIER-KRIESCHE HU, BALIGA R, KAPLAN B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation (2003) 75(8):1291-1295.
36. ABBOTT KC, YUAN CM, TAYLOR AJ, CRUESS DF, AGODOA LY: Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am. Soc. Nephrol. (2003) 14(9):2358-2365.
37. KIBERD B, KEOUGH-RYAN T, PANEK R: Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am. J. Transplant. (2003) 3(11):1393-1399.
38. CORESH J, WEI GL, MCQUILLAN G et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. (2001) 161(9):1207-1216.
39. TONELLI M, BOHM C, PANDEYA S, GILL J, LEVIN A, KIBERD BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am. J. Kidney Dis. (2001) 37(3):484-489.
40. SARNAK MJ, CORONADO BE, GREENE T et al.: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. (2002) 57(5):327-335.
41. CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Press.ure: the JNC 7 report. JAMA (2003) 289(19):2560-2572.
42. K/DOQI Clinical Practice Guidelines on Hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. (2004) 43(5Suppl. 1):S1.
43. AGARWAL R, NISSENSON AR, BATLLE D, COYNE DW, TROUT JR, WARNOCK DG: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med. (2003) 115(4):291-297.
44. ROCCO MV, FLANIGAN MJ, BEAVER S et al.: Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. Am J Kidney Dis (1997) 30(2):165-173.
45. ZAGER PG, NIKOLIC J, BROWN RH et al.: 'U' curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. (1998) 54(2):561-569.
46. PORT FK, HULBERT-SHEARON TE, WOLFE RA et al.: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am. J. Kidney Dis. (1999) 33(3):507-517.
47. TOZAWA M, ISEKI K, ISEKI C, TAKISHITA S: Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. (2002) 61(2):717-726.
48. GUNAL AI, DUMAN S, OZKAHYA M et al.: Strict volume control normalizes hypertension in peritoneal dialysis patients. Am. J. Kidney Dis. (2001) 37(3):588-593.
49. AHMAD S: Dietary sodium restriction for hypertension in dialysis patients. Semin. Dial. (2004) 17(4):284-287.
50. CHARRA B, TERRAT JC, VANEL T et al.: Long thrice weekly hemodialysis: the Tassin experience. Int. J. Artif. Organs (2004) 27(4):265-283.
51. MCGREGOR DO, BUTTIMORE AL, NICHOLLS MG, LYNN KL: Ambulatory blood pressure monitoring in patients receiving long, slow home haemodialysis. Nephrol. Dial. Transplant. (1999) 14(11):2676-2679.
52. ZAZGORNIK J, BIESENBACH G, FORSTENLEHNER M, STUMMVOLL K: Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT). Clin. Nephrol. (1997) 48(6):337-340.
53. GRIFFITH TF, CHUA BS, ALLEN AS, KLASSEN PS, REDDAN DN, SZCZECH LA: Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. (2003) 42(6):1260-1269.
54. FOLEY RN, HERZOG CA, COLLINS AJ, UNITED STATES RENAL DATA SYSTEM: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. (2002) 62(5):1784-1790.
55. SCHWENGER V, ZEIER M, RITZ E: Hypertension after renal transplantation. Curr. Hypertens. Rep. (2001) 3(5):434-439.
56. OLYAEI AJ, DEMATTOS AM, BENNETT WM: A practical guide to the management of hypertension in renal transplant recipients. Drugs (1999) 58(6):1011-1027.
57. EBPG EXPERT GROUP ON RENAL TRANSPLANTATION: European best practice guidelines for renal transplantation. Nephrol. Dial. Transplant. (2002) 17(Suppl. 4):1-25.
58. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P: Lipoprotein metabolism and renal failure. Am. J. Kidney Dis. (1993) 21(6):573-592.
59. TOMURA S, NAKAMURA Y, DOI M et al.: Fibrinogen, coagulation Factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am. J. Kidney Dis. (1996) 27:848-854.
60. ISEKI K, YAMAZATO M, TOZAWA M, TAKISHITA S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. (2002) 61(5):1887-1893.
61. LOWRIE EG, LEW NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. (1990) 15(5):458-482.
62. BROWN JH, MURPHY BG, DOUGLAS AF et al.: Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron. (1997) 75(3):277-282.
63. Executive Summary of The Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2499.
64. CUI Y, BLUMENTHAL RS, FLAWS JA et al.: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. (2001) 161(11):1413-1419.
65. HOLDAAS H, FELLSTROM B, JARDINE AG et al.: Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet (2003) 361(9374):2024-2031.
66. JARDINE AG, HOLDAAS H, FELLSTROM B et al.: ALERT Study Investigators: Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am. J. Transplant. (2004) 4(6):988-995.
67. TONELLI M, MOYE L, SACKS FM, KIBERD B, CURHAN G and the CHOLESTEROL AND RECURRENT EVENTS (CARE) TRIAL INVESTIGATORS: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann. Intern. Med. (2003) 138(2):98-104.
68. BAIGENT C, LANDRY M: Study of Heart and Renal Protection (SHARP). Kidney Int. Suppl. (2003) 84:S207-S210.
69. STEPHENSON JM, KENNY S, STEVENS LK, FULLER JH, LEE E: Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet. Med. (1995) 12(2):149-155.
70. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. (1995) 47:1703-1720.
71. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352:837-853.
72. WU MS, YU CC, WU CH, HAUNG JY, LEU ML, HUANG CC: Pre-dialysis glycemic control is an independent predictor of mortality in Type II diabetic patients on continuous ambulatory peritoneal dialysis. Perit. Dial. Int. (1999) 19(Suppl. 2):S179-S183.
73. WU MS, YU CC, YANG CW et al.: Poor pre-dialysis glycaemic control is a predictor of mortality in Type II diabetic patients on maintenance haemodialysis. Nephrol. Dial. Transplant. (1997) 12(10):2105-2110.
74. FOLEY RN, PARFREY PS: Cardiac disease in the diabetic dialysis patient. Nephrol. Dial. Transplant. (1998) 13(5):1112-1113.
75. BAYES B, LAUZURICA R, GRANADA ML et al.: Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation (2004) 78(1):26-30.
76. KASISKE BL, SNYDER JJ, GILBERTSON D, MATAS AJ: Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. (2003) 3(2):178-185.
77. ANTMAN EM, ANBE DT, ARMSTRONG PW et al.: American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation (2004) 110(5):588-636.
78. K/DOQI Clinical Practice Guidelines for in chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. (2002) 39:S1.
79. MURPHY SW: Management of heart failure and coronary artery disease in patients with chronic kidney disease. Semin. Dial. (2003) 16:165-172.
80. KASISKE BL, CANGRO CB, HARIHARAN S et al.: American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am. J. Transplant. (2001) 1(Suppl. 2):3-95.
81. GASTON RS, DANOVITCH GM, ADAMS PL et al.: The report of a national conference on the wait list for kidney transplantation. Am. J. Transplant. (2003) 3(7):775-785.
82. ASPELIN P, AUBRY P, FRANSSON SG, STRASSER R, WILLENBROCK R, BERG KJ: Nephrotoxicicy in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N. Engl. J. Med. (2003) 348(6):491-499.
83. TEPEL M, ZIDEK W: N-Acetylcysteine in nephrology; contrast nephropathy and beyond. Curr. Opin. Nephrol. Hypertens. (2004) 13:649-654.
84. MUELLER C, BUERKLE G, BUETTNER HJ et al.: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch. Intern. Med. (2002) 162(3):329-336.
85. FREDA BJ, TANG WH, VAN LENTE F, PEACOCK WF, FRANCIS GS: Cardiac troponins in renal insufficiency: review and clinical implications. J. Am. Coll. Cardiol. (2002) 40(12):2065-2071.
86. GOICOECHEA M, DE VINUESA SG, GOMEZ-CAMPDERA F, LUNO J: Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int. Suppl. (2005) (93):S35-S38.
87. AVILES RJ, ASKARI AT, LINDAHL B et al.: Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N. Engl. J. Med. (2002) 346(26):2047-2052.
88. LOCATELLI F, ALJAMA P, BARANY P et al.: European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. (2004) 19(Suppl. 2):ii1-47.
89. STENVINKEL P, PECOITS-FILHO R, LINDHOLM B: Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J. Am. Soc. Nephrol. (2003) 14(7):1927-1939.
90. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med (2000) 342(20):1478-1483.
91. OH J, WUNSCH R, TURZER M et al.: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation (2002) 106(1):100-105.
92. BLACHER J, GUERIN AP, PANNIER B, MARCHAIS SJ, LONDON GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension (2001) 38(4):938-942.
93. WANG AY, WANG M, WOO J et al.: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J. Am. Soc. Nephrol. (2004) 15(8):2186-2194.
94. RAGGI P, BOULAY A, CHASANTABER S et al.: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J. Am. Coll. Cardiol. (2002) 39(4):695-701.
95. STOMPOR T, PASOWICZ M, SULOWICZ W et al.: Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am. J. Kidney Dis. (2004) 44(3):517-528.
96. SHARPLES EJ, PEREIRA D, SUMMERS S et al.: Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am. J. Kidney Dis. (2004) 43(2):313-319.
97. CICE G, FERRARA L, DI BENEDETTO A et al.: Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. (2001) 37(2):407-411.
98. CICE G, FERRARA L, D'ANDREA A et al.: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J. Am. Coll. Cardiol. (2003) 41(9):1438-1444.
99. ZUANETTI G, MAGGIONI AP, KEANE W, RITZ E: Nephrologists neglect administration of betablockers to dialysed diabetic patients. Nephrol. Dial. Transplant. (1997) 12(12):2497-500.
100. HERZOG CA, MA JZ, COLLINS AJ: Long-term survival dialysis patients receiving thrombolytic threrapy for acute myocardial infarction in the United States. J. Am. Soc. Nephrol. (1999) 10:166A. (Abstract).
101. HERZOG CA, MA JZ, COLLINS AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N. Engl. J. Med. (1998) 339(12):799-805.
102. HERZOG CA, MAJZ, COLLINS AJ: Long-term survival of renal transplant recipients in the United States after acute myocardial infarction. Am. J. Kidney Dis. (2000) 36(1):145-152.
103. BERGER AK, DUVAL S, KRUMHOLZ HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J. Am. Coll. Cardiol. (2003) 42(2):201-208.
104. SHLIPAK MG, HEIDENREICH PA, NOGUCHI H, CHERTOW GM, BROWNER WS, MCCLELLAN MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann. Intern. Med. (2002) 137(7):555-562.
105. HERZOG CA: Acute myocardial infarction in patients with end-stage renal disease. Kidney Int. Suppl. (1999) 71:S130-S133.
106. MENON V, SARNAK MJ, LESSARD D, GOLDBERG RJ: Recent trends in hospital management practices and prognosis after acute myocardial infarction in patients with kidney disease. Am. J. Cardiol. (2004) 94(10):1290-1293.
107. BEST PJ, LENNON R, GERSH BJ et al.: Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am. Heart J. (2003) 146(2):345-350.
108. MALMBERG K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br. Med. J. (1997) 314(7093):1512-1515.
109. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. (2004) 351(13):1285-1295
110. MCCULLOUGH PA: Acute coronary syndromes in patients with renal failure. Curr. Cardiol. Rep. (2003) 5(4):266-270.
111. SADEGHI HM, STONE GW, GRINES CL et al.: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation (2003) 108(22):2769-2775.
112. SZCZECH LA, BEST PJ, CROWLEY E et al.: Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation (2002) 105(19):2253-2258.
113. HERZOG CA, MA JZ, COLLINS AJ: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation (2002) 106(17):2207-2211.
114. SZCZECH LA, BEST PJ, CROWLEY E et al.: Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation (2002) 105(19):2253-2258.
115. SZCZECH LA, REDDAN DN, OWEN WF et al.: Differential survival after coronary revascularization procedures among patients with renal insufficiency Kidney Int. (2001) 60(1):292-299.
116. AZAR RR, PRPIC R, HO KK et al.: Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am. J. Cardiol (2000) 86(5):485-489.
117. GRUBERG L, WAKSMAN R, AJANI AE et al.: The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with chronic renal failure. J. Am. Coll. Cardiol. (2001) 38(4):1049-1053.
118. BEST PJ, BERGER PB, DAVIS BR et al.: Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J. Am. Coll. Cardiol. (2004) 44(9):1786-1791.
119. ASCIONE R, NASON G, AL-RUZZEH S, KO C, CIULLI F, ANGELINI GD: Coronary revascularization with or without cardiopulmonary bypass in patients with preoperative nondialysis-dependent renal insufficiency. Ann. Thorac. Surg. (2001) 72(6):2020-2025.
120. HERZOG CA, MA JZ, COLLINS AJ: Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation (2004) 109 (23):2866-2871.
121. GOLDFARB-RUMYANTZEV A, HURDLE JF, SCANDLING J et al.: Duration of end-stage renal disease and kidney transplant outcome. Nephrol. Dial. Transplant. (2005) 20(1):167-175.